In breast carcinoma cells, but not in CRC cells, YBX1 was found to bind to the promoter and act as a transcriptional activator of the EGFR gene.31 YBX1 mediated resistance to anti-ERBB2 therapy via a complex, RSK-dependent mechanism32 and prevents apoptosis in ERBB2-overexpressing breast cancer cells.33 In contrast to the well-known link between YBX1 and EGFR in breast or lung cancer, there is little knowledge about the interaction of YBX1 and the EGFR family in CRC. The gene discussed is YBX1; the disease is breast carcinoma.